Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Valmet to deliver a tissue paper making line, tissue converting equipment and a biomass boiler to Suzano Papel e Celulose in Brazil

Valmet Oyj’s press release on January 30, 2024 at 9:30 a.m. EETValmet will deliver a complete tissue line including a tissue making line and converting equipment to Suzano Papel e Celulose in Brazil. The order also includes a biomass boiler. This is Valmet’s first combined order with tissue making and tissue converting lines after the acquisition of tissue converting business in late 2023 . The tissue order also includes an extensive automation package, flow control

Update on Woodspin ramp-up – the development of the raw material production process advances

SPINNOVA PLC, PRESS RELEASE, 30 January 2024, 9:30 a.m. EET Update on Woodspin ramp-up – the development of the raw material production process advances The ramp-up of Woodspin’s first factory is progressing. As announced in August, the raw material provider Suzano has been working on the eucalyptus-based micro fibrillated cellulose (MFC) raw material specifications, and now, recent tests have been successful. “We are pleased that Suzano has passed some important milestones related to the MFC raw material development. Spinnova continues to finalize the fibre and textile material

Capitainer recruits application specialist to develop new test protocols and to support laboratories in their implementation of qDBS

Capitainer, a leading Swedish medtech company specialising in advanced self-sampling solutions, has recruited Johan Olausson as an applications specialist in clinical chemistry. Through his deep knowledge and experience gained from working with several leading diagnostics suppliers for central laboratories, Capitainer will increase the pace of development of new test protocols for the company's products.Johan Olausson has held diverse roles within research and clinical diagnostics since 2005, with a focus on clinical chemistry. Besides employment as hospital biochemist at Östersund Hospital

Kesko's share-based commitment and incentive plans for 2024-2027

Kesko Corporation's Board of Directors has decided that the target group for the 2024-2025 performance period of Kesko’s share-based commitment and incentive plan PSP (Performance Share Plan) will comprise approximately 60  key members of Kesko’s management. The Board also decided that the target group for the KPSP (Key Personnel Share Plan) for the 2024 performance period will comprise approximately 160  other key persons at Kesko. The Board also confirmed the criteria for 2024 for the PSP 2023-2026, PSP 2024-2027 and KPSP 2024. The Board also decided to initiate a Restricted Share Pool (RSP)

Össur hf: Annual Report 2023

Announcement no. 4/2024 Annual Report 2023 30 January 2024 Annual Report 2023 Össur’s Annual Report 2023 has just been published and is available for download at the link below. An online version of the Annual Report 2023 is available at https://annual-report.ossur.com/ Further information David Hreidarsson, VP of Investor Relations, IR@ossur.com, +354 661 8225 Össur press releases by e-mail If you wish to receive Össur press releases by e-mail, please register at http://www.ossur.com/investors About Össur Össur (Nasdaq Copenhagen: OSSR) is a leading global

Loyal Solutions announces financial results for the first half of the financial year 2023/24

Danish SaaS company Loyal Solutions delivers 65% revenue growth and 99% gross margin growth for first half year (1/7-31/12 2023),  while maintaining stable operating expenses.CEO Peter Kisbye comments: “In the period 1 July 2023 – 31 December 2023 (“the Period”) the Company delivered the following results: · 65% revenue growth year on year · 99% growth in gross margin (Revenue-CoGS) · Stable OPX year on year (+3%) · Growth in annual recurring revenue (ARR) of 7% · EBITDA of TDKK -2.358 vs budget of TDKK -5.373 and last year TDKK -7.173 · Result of TDKK -3.648 vs

Planmeca Viso® G3 now available – Enter a new dimension

The wait is over – Planmeca Viso® G3 is here. As the newest member of the Planmeca Viso® family of world-class imaging units, Planmeca Viso G3 offers innovative features, fantastic usability, and outstanding image quality for a cutting-edge CBCT imaging experience. Now available for deliveries. Planmeca Viso® G3 is the newest member of the popular Planmeca Viso®  family of CBCT units, which are the choice imaging units of dental professionals around the world. It is a truly multifunctional CBCT device, covering all

Repurchases of shares by Concentric AB during week 4, 2024

Between 22 January 2024 and 26 January 2024 Concentric AB (LEI code 5493002G9GMTKIP3PW19) (“Concentric”) has repurchased in total 22,459 own shares (ISIN: SE0003950864) as part of the repurchase program initiated by the Board. The repurchases form part of the repurchase program of a maximum of 3,519,172 own shares for a total maximum amount of SEK 150,000,000 that Concentric announced on 26 July 2023. The repurchase program, which runs between 31 July 2023 and 31 March 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated

VENOMAID EXTENDS ITS SEED ROUND TO A TOTAL OF $ 1.8 M FOR AFFORDABLE AND RAPID SNAKEBITE DIAGNOSTICS

    Copenhagen, Denmark, 30th January 2024, World NTD Day – VenomAid Diagnostics (Abbr.: VenomAid), the Danish company developing snakebite diagnostics, announced today that it has successfully extended its seed round to $1.8 million with continued support from a select group of private Business Angels and the philanthropic venture fund Good Ventures LLC. The announcement comes on the annual World NTD day, which serves as a catalyst to translate awareness into action and secure increased resources for neglected tropical diseases (NTDs).   Founded in 2018 with a

Invitation to presentation of Balder’s year-end report 2023

On 9 February at 08:00 (CET), Fastighets AB Balder (publ) will be publishing its year-end report for January to December 2023. The report will be published at balder.se . On the same day at 08:45, Balder’s CEO Erik Selin and CFO Ewa Wassberg will be holding an online presentation and telephone conference that analysts, investors, media and other stakeholders are welcome to attend. The presentation will be held in English, and during the telephone conference there will be an opportunity for representatives from the financial

SciBase initiates collaboration with Inderes for commissioned research

STOCKHOLM, SWEDEN, - January 30, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in early detection and prevention in dermatology initiates cooperation with Inderes (www.inderes.se) for ongoing services related to commissioned research. This collaboration aims at providing high-quality equity research on SciBase Holding AB stock.The research reports, analyst comments and interview videos will be published and made available on inderes.se , inderes.dk  and inderes.fi  with over 70,000 active members, as well as

Interim Results to 31 October 2023

30 January 2024   WeCap plc (formerly IamFire plc)   AQSE: WCAP   (“WeCap” or the “Company”)     UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 OCTOBER 2023       CHAIRMAN’S STATEMENT I am pleased to present the interim results for WeCap plc (AQSE: WCAP) (formerly IamFire plc) for the period of 30 April 2023 to 31 October 2023.  The period was dominated by the continued support for the Company’s primary investment, WeShop Holdings Limited (“WeShop”).  In May 2023 the Company subscribed for a further £150k of Convertible Loan Notes (“CLN”)

Transaction in Own Shares

    30 January 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |29/01/2024|+-----------------------------------------------------------

Change in JM Group's business segments

As of the first quarter of 2024, JM Construction will be absorbed into the group since the business no longer is of such a scope that it constitutes its own business segment.To date, JM has followed up and reported on its operations based on six business segments: JM Residential Stockholm, JM Residential Sweden, JM Norway, JM Finland, JM Property Development and JM Construction.   As the scope of the operations in JM Construction has decreased, JM has changed its internal governance and follow-up of operations as of the first quarter of 2024 and subsequently changed the reporting for

JM Year-end Report January–December 2023

GOOD LIQUIDITY AND SIGNIFICANT SURPLUS VALUES· Revenue amounted to SEK 13,851m (16,385). · Operating profit decreased to SEK 732m (2,064) and was burdened by impairment in development and project properties of SEK −258m (–). The operating margin decreased to 5.3 percent (12.6). · Profit before tax decreased to SEK 632m (1,994), and profit after tax decreased to SEK 433m (1,575). · Return on equity for the past twelve months amounted to 5.0 percent (17.9). · Earnings per share amounted to SEK 6.70 (23.40). · Consolidated cash flow including net investment in properties

Össur hf: Interim Report Q4 2023

Announcement no. 3/2024 Interim report Q4 2023 30 January 2024 Sveinn Sölvason, President and CEO, Comments: “I’m very pleased to end the year on a solid quarter with organic growth of 9%, driven by continued strong performance in Prosthetics and Patient Care. Organic growth for the full year was 9% and in 2023 we have grown the business in all regions and business segments. We reached a major milestone in our journey to become an increasingly patient focused company, addressing chronic mobility challenges in a broader context, by acquiring FIOR & GENTZ in January 2024. With the

Nordnet publishes its Year-end Report 2023

Nordnet AB (publ) today publishes its Year-end report 2023. The full report is available at www.nordnetab.com.“The fourth quarter was good for both for Nordnet and private savers. The stock markets recovered over the last three months of the year due to slowing inflation and hopes that interest rates have peaked. During the quarter, 38,600 new savers chose Nordnet as their platform. At the start of 2024, our customers' savings capital amounted to SEK 825 billion, a new record level. This record builds on continuous positive net savings, as well as rising Nordic stock markets. The value of

Notice of Q4 2023 Earnings Release and Conference Call

LANCASHIRE HOLDINGS LIMITED   30 January 2024 Hamilton, Bermuda    Notice of Q4 2023 Earnings Release and Conference Call Lancashire Holdings Limited (“Lancashire” or “the Company”) will be announcing its 2023 fourth quarter earnings release at 07:00 GMT on Wednesday 6 March 2024 and hosting an analyst and investor conference call at 14:00 UK time / 09:00 EST on Wednesday 6 March 2024. The conference call will be hosted by Lancashire management. Please note that conference call participants are required to register in advance to access either the audio conference call

Nordnet AB (publ) gives notice of early redemption of Additional Tier 1 (AT1) capital notes with ISIN SE0012350627

Nordnet AB (publ) (“Nordnet”) announces that it will carry out an early redemption of all outstanding additional tier 1 capital notes issued on 21 March 2019 with ISIN SE0012350627, with a total outstanding nominal amount of SEK 500,000,000 (the “Notes”) in accordance with the terms and conditions of the Notes (the “Terms and Conditions”).Nordnet will, in the near future, send an irrevocable notice of early redemption to all directly registered owners (Sw. direktregistrerad ägare) and registered authorised nominees (Sw. förvaltare) in the debt register for the Notes kept by Euroclear Sweden.

Kindred unveils strategic partnership with Stats Perform to power Kindred Sportsbook Platform

Kindred has signed an extensive agreement with Stats Perform which will give access to Stats Perform’s full RunningBall and Opta product suite. This includes comprehensive, real-time official sports data feeds and statistics, allowing Kindred’s customers a frictionless in-play betting experience as well as trusted proposition betting markets centred around player performance, a highly innovative live bet-builder product.Kindred Group plc (Kindred) continues the development of its proprietary sportsbook platform, Kindred Sportsbook Platform (KSP), by signing a wide-ranging agreement with

Irisity Awarded Renewal and Expansion of Perimeter Security Contract in the UK

Irisity AB (publ), a provider of AI-driven video data management software, reports a renewal and expansion of a perimeter security contract with a UK-based home appliance manufacturer. It is an Annual Recurring Revenue (ARR) contract, marking the fourth year of delivering a perimeter security deployment in partnership with a UK-based integration partner.FOR IMMEDIATE RELEASE     Irisity Awarded Renewal and Expansion of Perimeter Security Contract in the UK    Gothenburg, Sweden – January 30, 2024 – Irisity AB (publ), a provider of AI-driven video data management software,

Implantica’s RefluxStop™ procedure now available in Norway

Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces that the RefluxStop™ procedure is now available at the Akershus University Hospital in Norway.Earlier this month, the RefluxStop™ procedure, a new cutting-edge surgical treatment for GERD, was performed on five patients by Dr. Robin Gaupset and Dr. Lars Eftang at Akershus University Hospital in Oslo. Dr. Gaupset says, “We believe RefluxStop™ has the potential to offer a superior surgical treatment against GERD/reflux, with fewer side effects compared to current alternatives.

Proposals of the Shareholders' Nomination Board of Sitowise for the Annual General Meeting 2024

Sitowise Group Plc Stock Exchange Release     Other information disclosed according to the rules of the Exchange      30 January 2024 at 9.00 am EET The Shareholders' Nomination Board of Sitowise Group Plc has submitted to the Board of Directors its proposals for the Annual General Meeting which is planned to be held on 4 April 2024. Proposal on the remuneration of the members of the Board of Directors The Shareholders' Nomination Board proposes that the members of the Board of Directors and its committees will be paid for the term of office ending in the Annual General Meeting

Realisation of Kesko's share-based commitment and incentive plans KPSP 2021, RSP 2021 and RSP 2022

Kesko Corporation’s Board of Directors has decided, based on the fulfilment of the performance criteria for the 2021 performance period of the KPSP 2021, to grant a total of 169,094 Kesko B shares to the key persons of the KPSP 2021 target group and in accordance with the terms and conditions of the RSP 2021 plan, a total of  31,669 Kesko B shares and in accordance with RSP 2022 plan, a total of 1,000 Kesko B shares to key persons in the company. The share numbers represent gross earnings, from which the applicable taxes are deducted, and the remaining net amount is paid to the participants

There are no items matching the current filter
There are no more items matching the current filter
Back to top